US FDA accepts Biocon's cancer drug application for review
Posted by
www.biotecnika.org
Biocon and Mylan's proposed biosimilar bevacizumab, a cancer drug, is
expected to be the third biosimilar from the partnered portfolio for
patients in the US.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/us-fda-accepts-biocons-cancer-drug-application-for-review/articleshow/74545638.cms
Subscribe to:
Post Comments (Atom)
Post a Comment